These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32584958)

  • 41. Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia.
    Jandourek A; Smith A; Llorens L; Thye DA; Eckburg PB; Friedland HD
    Hosp Pract (1995); 2014 Feb; 42(1):75-8. PubMed ID: 24566599
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and microbiological end points in the treatment of pneumonia.
    Musher DM
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S207-9. PubMed ID: 18986291
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia.
    Covington PS; Davenport JM; Andrae DA; Stryjewski ME; Turner LL; McIntyre G; Almenoff J
    J Antimicrob Chemother; 2013 Nov; 68(11):2691-3. PubMed ID: 23749951
    [No Abstract]   [Full Text] [Related]  

  • 44. Ceftaroline Fosamil for the Treatment of
    Vazquez JA; Maggiore CR; Cole P; Smith A; Jandourek A; Friedland HD
    Infect Dis Clin Pract (Baltim Md); 2015 Jan; 23(1):39-43. PubMed ID: 25574117
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Emerging antibiotics for community-acquired pneumonia.
    Liapikou A; Cilloniz C; Palomeque A; Torres T
    Expert Opin Emerg Drugs; 2019 Dec; 24(4):221-231. PubMed ID: 31657962
    [No Abstract]   [Full Text] [Related]  

  • 46. [Switch therapy for community acquired pneumonia].
    Aoshima M
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():326-30. PubMed ID: 17455640
    [No Abstract]   [Full Text] [Related]  

  • 47. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good.
    Corey GR; Stryjewski ME
    Clin Infect Dis; 2011 Jun; 52 Suppl 7():S469-76. PubMed ID: 21546623
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Shortening antibiotic duration for community acquired pneumonia.
    Melo L; Oliveira S
    Eur J Intern Med; 2018 May; 51():e21-e22. PubMed ID: 29454484
    [No Abstract]   [Full Text] [Related]  

  • 49. Short-course treatment of community-acquired pneumonia.
    Mandell LA; File TM
    Clin Infect Dis; 2003 Sep; 37(6):761-3. PubMed ID: 12955635
    [No Abstract]   [Full Text] [Related]  

  • 50. Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice.
    Ramirez JA; Tzanis E; Curran M; Noble R; Chitra S; Manley A; Kirsch C; McGovern PC
    Clin Infect Dis; 2019 Aug; 69(Suppl 1):S33-S39. PubMed ID: 31367741
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Solithromycin: A novel ketolide antibiotic.
    Buege MJ; Brown JE; Aitken SL
    Am J Health Syst Pharm; 2017 Jun; 74(12):875-887. PubMed ID: 28432048
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Community-acquired pneumonia: is it time to shorten the antibiotic treatment?
    Esposito S; Fiore M
    Expert Rev Anti Infect Ther; 2007 Dec; 5(6):933-8. PubMed ID: 18039078
    [No Abstract]   [Full Text] [Related]  

  • 53. Community acquired pneumonia.
    Loeb M
    Clin Evid; 2002 Jun; (7):1358-68. PubMed ID: 12230751
    [No Abstract]   [Full Text] [Related]  

  • 54. Drugs of choice for community-acquired bacterial pneumonia.
    Med Lett Drugs Ther; 2007 Jul; 49(1266):62-4. PubMed ID: 17652999
    [No Abstract]   [Full Text] [Related]  

  • 55. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL).
    Barrera CM; Mykietiuk A; Metev H; Nitu MF; Karimjee N; Doreski PA; Mitha I; Tanaseanu CM; Molina JM; Antonovsky Y; Van Rensburg DJ; Rowe BH; Flores-Figueroa J; Rewerska B; Clark K; Keedy K; Sheets A; Scott D; Horwith G; Das AF; Jamieson B; Fernandes P; Oldach D;
    Lancet Infect Dis; 2016 Apr; 16(4):421-30. PubMed ID: 26852726
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monotherapy in severe community-acquired pneumonia: is it worthy?
    Torres A
    Chest; 2005 Jul; 128(1):10-3. PubMed ID: 16002907
    [No Abstract]   [Full Text] [Related]  

  • 57. Severe community acquired pneumonia.
    Mills GD; Laing R
    BMJ; 2006 Dec; 333(7580):1181-2. PubMed ID: 17158360
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience.
    Ramani A; Udeani G; Evans J; Jandourek A; Cole P; Smith A; David Friedland H
    J Chemother; 2014 Aug; 26(4):229-34. PubMed ID: 24650326
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Summary of ceftaroline fosamil clinical trial studies and clinical safety.
    File TM; Wilcox MH; Stein GE
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S173-80. PubMed ID: 22903949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Community-acquired pneumonia versus healthcare-associated pneumonia. The returning pendulum.
    Wunderink RG
    Am J Respir Crit Care Med; 2013 Oct; 188(8):896-8. PubMed ID: 24127797
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.